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Abstract In cardiac and skeletal muscle Ca2+ translocation
from cytoplasm into sarcoplasmic reticulum (SR) is accom-
plished by different Ca2+-ATPases whose functioning involves
the formation and decomposition of an acylphosphorylated
phosphoenzyme intermediate (EP). In this study we found that
acylphosphatase, an enzyme well represented in muscular tissues
and which actively hydrolyzes EP, had different effects on heart
(SERCA2a) and fast twitch skeletal muscle SR Ca2+-ATPase
(SERCA1). With physiological acylphosphatase concentrations
SERCA2a exhibited a parallel increase in the rates of both ATP
hydrolysis and Ca2+ transport; in contrast, SERCA1 appeared
to be uncoupled since the stimulation of ATP hydrolysis matched
an inhibition of Ca2+ pump. These different effects probably
depend on phospholamban, which is associated with SERCA2a
but not SERCA1. Consistent with this view, the present study
suggests that acylphosphatase-induced stimulation of SERCA2a,
in addition to an enhanced EP hydrolysis, may be due to a
displacement of phospholamban, thus to a removal of its
inhibitory effect.
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1. Introduction
In both cardiac and skeletal muscle active calcium transport
by sarcoplasmic reticulum (SR) is mediated by an ATPase
enzyme of about 100 kDa which serves as an energy trans-
ducer and a translocator of calcium ions. Ca2 transport and
ATP hydrolysis are coupled through a complex series of ele-
mentary steps involving the formation and the decomposition
of a phosphoenzyme intermediate (EP) [1], which has been
identi¢ed as an acylphosphate, since phosphorylation takes
places at a carboxyl group of an aspartic acid residue [2,3].
Cardiac SR Ca2-ATPase (SERCA2a), unlike the analogous
skeletal enzyme (SERCA1), is regulated by a 22 kDa integral
membrane protein named phospholamban (PLN), whose
phosphorylation by cAMP-dependent protein kinase (PKA)
leads to an increase in the rate of active Ca2 transport.
Thus, unphosphorylated PLN is believed to function as a
calcium pump inhibitor that becomes inactive upon phospho-
rylation [4^6]. Many laboratories that have studied the e¡ect
of PKA-catalyzed phosphorylation of PLN on the kinetics of
calcium uptake or Ca2-ATPase activity have reported a de-
crease in the KmCa2 or an increase in VmaxCa2 or both these
e¡ects [7^13].
Acylphosphatase (EC 3.6.1.7) is a widespread cytosolic en-
zyme, well represented in skeletal and heart muscle, that cata-
lyzes the hydrolysis of the carboxylphosphate bond of acyl-
phosphates such as 3-phosphoglyceroyl phosphate [14],
carbamoyl phosphate [15] and succinoyl phosphate [16]. In
addition to the above soluble, low molecular weight substrates
we found that this enzyme hydrolyzed the phosphorylated
intermediates of various transport ATPases, notably those
of erythrocyte membrane [17] and heart sarcolemma Ca2-
ATPase [18]. More recently we reported that acylphosphatase
actively hydrolyzed the phosphoenzyme of the cardiac SR
Ca2 pump, with an apparent Km in the order of 1037 M,
suggesting a high a⁄nity of our enzyme for this special sub-
strate [19]. This caused us to study the e¡ect of acylphospha-
tase on the functional properties of the heart SR Ca2 pump.
The results obtained indicated that in unphosphorylated car-
diac SR vesicles acylphosphatase enhanced the rate of ATP
hydrolysis and Ca2 uptake. On the other hand, in vesicles
whose phospholamban was PKA-phosphorylated, acylphos-
phatase still stimulated the rate of Ca2 uptake and ATP
hydrolysis but to a lesser extent. As an interpretation of these
¢ndings we proposed that acylphosphatase, in addition to the
stimulatory e¡ect due to its catalytic activity, could also act
through the removal of phospholamban inhibition. In fact
acylphosphatase, a small protein of about 11 kDa, contains
a structural motif where 12 residues (from position 55 to 66)
form an amphipathic K-helix with a prevalence of basic
groups [20]. This structure resembles that of the phospho-
lamban cytoplasmic 1A domain [21] which is essential for
the association of phospholamban with SERCA2a, so we
supposed that acylphosphatase could interact with this trans-
port system taking the place of unphosphorylated phos-
pholamban whose inhibitory e¡ect would therefore be re-
moved.
The present paper reports the studies that we performed in
order to verify the above hypothesis and to probe more deeply
the interactions of acylphosphatase with the heart SR Ca2
pump.
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2. Materials and methods
PKA from rabbit muscle, Tris-ATP, protein G-Sepharose 4B Fast
£ow were from Sigma.
[Q-32P]ATP and 45CaCl2 were obtained from DuPont NEN. Mono-
clonal (mouse) anti-SERCA2a ATPase antibody (IgG2a) (Clone 2A7-
A1, ascites £uid) was from A⁄nity Bioreagents, Inc. Anti-mouse IgG
(donkey) peroxidase conjugate was from Amersham, while anti-rabbit
IgG (goat) peroxidase conjugate was from Calbiochem. Nitrocellulose
¢lters and membranes were obtained from Sartorius. Enhanced chem-
oluminescence assay (ECL) was from Amersham.
2.1. Acylphosphatase: puri¢cation and some properties
Acylphosphatase was puri¢ed from bovine heart according to Ram-
poni et al. [22] for the extraction, and according to Stefani et al. for
the other steps [23]. The acylphosphatase Asn-41 mutant to Ser,
Asn41Ser, was obtained by site-directed mutagenesis and puri¢ed by
Modesti et al. [24]. The properties of this mutant are reported in
Section 3. Anti-acylphosphatase antibodies were raised in rabbits us-
ing the recombinant protein [24] and puri¢ed by a⁄nity chromatog-
raphy [25].
2.2. Preparation of SR vesicles (SRVs)
Cardiac and skeletal SRVs were isolated from heart and fast twitch
skeletal muscle (adductor magnus) of rabbit according to Jones et al.
[26] and measured for protein by the method of Bradford [27]. To
induce phospholamban phosphorylation cardiac SRVs (0.5 mg/ml)
were incubated in 40 mM Tris-HCl, pH 7.4, 120 mM KCl, 5 mM
MgCl2, 5 mM Tris-ATP with 10 WM cAMP and 1 mg/ml PKA at
25‡C for 10 min. The reaction was terminated in ice. PLN phospho-
rylation was veri¢ed as previously described [19].
2.3. Preparation of phosphorylated intermediate of cardiac SR
Ca2+-ATPase and its incubation with acylphosphatase
Cardiac SRVs were phosphorylated by [Q-32P]ATP according to
Nediani et al. [19]. 0.15 mg/ml of phosphorylated SRVs was incubated
in 30 mM Tris-HCl, pH 7.4 at 37‡C for 30 s without and with di¡er-
ing amounts of acylphosphatase. The reaction was stopped with 10%
ice-cold trichloroacetic acid and the suspension was centrifuged at
13 000Ug for 5 min. Aliquots of the supernatants were taken to
measure free 32P radioactivity.
2.4. ATPase activity measurements
Ca2-ATPase activity was assayed as previously described [19]. In
our experimental conditions a free Ca2 concentration of approxi-
mately 10 WM was calculated using the equations of Katz et al.
[28]. The reaction was started by the addition of ATP or of an aliquot
of the vesicle suspension and stopped after 10 min with one volume of
ice-cold 20% trichloroacetic acid. Phosphate release from ATP was
measured by the malachite green procedure [29] in aliquots of the
supernatant.
2.5. Ca2+ in£ux measurements into SRVs
For these measurements the reaction mixture was the same as for
ATPase assays except that it included 45CaCl2 and 5 mM oxalate.
After 30 s of incubation at 37‡C, the vesicles were separated from
the medium by ¢ltration through a Millipore ¢lter (0.45 Wm pore size),
and then the ¢lter was immediately washed two times with 4 ml of ice-
cold 20 mM Tris-HCl, pH 7.4, 1 mM EGTA, and 100 mM KCl.
Oxalate-facilitated 45Ca uptake was measured as the di¡erence in
45Ca in£ux into vesicle at time zero and at the end of incubation.
Radioactivity trapped on the ¢lter was determined by liquid scintilla-
tion spectroscopy.
2.6. Coimmunoprecipitation and Western blot analysis of SERCA2a
and acylphosphatase
Cardiac specimens were homogenized in three volumes of immuno-
precipitation bu¡er (10 mM Tris-HCl, pH 7.0, 150 mM NaCl, 1%
Triton, 1 mM EGTA, 1 mM EDTA) with an Ultraturrax apparatus
for 90 s and then centrifuged at 36 000Ug for 30 min to remove
insoluble material. Solubilized protein fraction was incubated for 1 h
in ice with 5 Wl of monoclonal anti-SERCA2a antibody in the
presence of the Asn41Ser mutant of acylphosphatase or of its dena-
tured form. Immune complexes were collected on protein G-Sephar-
ose and washed four times in the immunoprecipitation bu¡er. Sam-
ples were resolved by 8% and 15% SDS-PAGE and transferred to
nitrocellulose membranes [30]. Immunorecognition was performed
with monoclonal (mouse) anti-SERCA2a antibody (1:1500), polyclo-
nal (rabbit) anti-human muscle acylphosphatase antibody (1:4000)
and secondary peroxidase-conjugated speci¢c antibodies. Immuno-
reactive bands were visualized by ECL detection reagent on a Biomax
Light-1 ¢lm (Kodak).
3. Results
Acylphosphatase used in the present study was a pure prod-
uct which had a speci¢c activity of 3650 U/mg protein using
benzoyl phosphate as substrate [31]. The Asn41Ser acylphos-
phatase mutant was almost completely devoid of catalytic
activity (speci¢c activity 10 U/mg protein using the above
substrate) but retained substrate binding ability and un-
changed three-dimensional structure with respect to the active
enzyme [32].
3.1. E¡ect of acylphosphatase on the phosphorylated
intermediate of cardiac SR Ca2+-ATPase
Fig. 1 shows the phosphate release from cardiac SR Ca2-
ATPase phosphoenzyme in the absence and in the presence of
di¡ering concentrations of acylphosphatase. These acylphos-
phatase/SRV protein ratios were chosen because they are
within the physiological range which, in the heart and in the
skeletal muscle, was estimated to be 80^130 U/mg of SRV
protein [33]. When acylphosphatase was present the release
of phosphate was always higher than the spontaneous hydrol-
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Table 1
E¡ect of acylphosphatase on cardiac and skeletal SR Ca2-ATPase activity
Acylphosphatase
(U/mg SRC protein)








0 66.67 þ 6.21 1.81 þ 0.09
10 76.58 þ 8.46 1.14 2.03 þ 0.22 1.12
20 85.92 þ 8.33 1.28 2.25 þ 0.15 1.24
30 95.39 þ 7.47 1.43 2.57 þ 0.24 1.42
40 107.67 þ 8.79 1.61 2.80 þ 0.13 1.54
50 116.09 þ 9.90 1.74 2.98 þ 0.07 1.64
75 129.04 þ 14.12 1.93 3.16 þ 0.18 1.74
100 147.11 þ 14.68 2.20 3.39 þ 0.27 1.87
Asn41Ser 94.67 þ 13.35 1.41 1.77 þ 0.07 ^
hd-Asn41Ser 68.53 þ 5.81 1.02 1.73 þ 0.09 ^
Values are means þ S.E.M. of six replicate determinations. Changes observed with di¡ering amounts of acylphosphatase were statistically signi¢cant
for both cardiac and skeletal Ca2-ATPase activity (P6 0.01 by one-way analysis of variance). hd: heat-denaturated.
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ysis, even at the lowest enzyme concentration, and rose sig-
ni¢cantly with increasing acylphosphatase/SRV protein ratio.
In contrast, no signi¢cant enhancement of phosphate release
was observed using the Asn41Ser mutant of acylphosphatase
at a concentration corresponding to 100 U of active enzyme
per mg of SRV.
3.2. Coimmunoprecipitation between cardiac Ca2+-ATPase and
the Asn41Ser mutant of acylphosphatase
When the cardiac solubilized protein fraction, used as a
source of Ca2-ATPase, and the Asn41Ser mutant of acyl-
phosphatase were incubated together, in the presence of
monoclonal anti-SERCA2a antibody, Western blot analysis
of the immunoprecipitate (Fig. 2) revealed two clear bands
at 110 kDa and 11 kDa, corresponding to SERCA2a and to
the acylphosphatase mutant, which indicates coimmunopre-
cipitation of these proteins. Only one band at 110 kDa was
observed when the above incubation was performed using the
heat-denatured form of the mutant. No positive band was
evident when anti-SERCA2a antibody was incubated only
with Asn41Ser, so immunoreactivity between these two pro-
teins could be excluded.
3.3. E¡ect of acylphosphatase on cardiac and skeletal SR
Ca2+-ATPase activity and Ca2+ transport
Table 1 shows that, as expected from our previous studies
[17,18], acylphosphatase signi¢cantly stimulated the rates of
Ca2-dependent ATP hydrolysis of both cardiac and skeletal
SR vesicles. With 100 U acylphosphatase per mg SRV pro-
tein, the concentration that gave maximal stimulation, the
increase over the control value was 120% for cardiac and
87% for skeletal muscle Ca2-ATPase activity. In the presence
of the Asn41Ser mutant of acylphosphatase, at the same pro-
tein concentration, cardiac Ca2-ATPase activity was still sig-
ni¢cantly increased (41% over the basal value), while skeletal
Ca2-ATPase activity was una¡ected. Using the heat-dena-
tured Asn41Ser mutant the stimulatory e¡ect on cardiac
SRVs disappeared.
As regards Ca2 uptake, acylphosphatase e¡ects were
markedly di¡erent depending on the use of cardiac or skeletal
muscle SRVs. Acylphosphatase addition to cardiac SRVs re-
sulted in a concentration-dependent enhancement of Ca2
transport which paralleled the stimulation of Ca2-ATPase
activity (Table 2). Also the Asn41Ser mutant (but not its
heat-denatured form) stimulated the Ca2 uptake by cardiac
SRVs, although to a lesser extent than the native enzyme
(60% over the control value against 100% obtained with the
active form). In contrast, in skeletal SR vesicles Ca2 uptake
was gradually and signi¢cantly inhibited at increasing
amounts of acylphosphatase while the Asn41Ser mutant did
not exert any e¡ect.
3.4. E¡ect of acylphosphatase on cardiac PKA-phosphorylated
SR vesicles
Also in this case acylphosphatase induced a concentration-
dependent increase in the rate of ATP hydrolysis and Ca2
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Table 2
E¡ect of acylphosphatase on cardiac and skeletal SR Ca2 uptake
Acylphosphatase
(U/mg SRV protein)
Cardiac SR Ca2 uptake
(nmol/min/mg SRV protein)
Skeletal SR Ca2 uptake
(Wmol/min/mg SRV protein)
0 80.82 þ 4.40 2.10 þ 0.05
20 103.85 þ 8.25 1.51 þ 0.02
50 131.54 þ 6.75 0.96 þ 0.01
75 161.87 þ 7.42 0.73 þ 0.04
100 172.31 þ 8.83 0.58 þ 0.03
Asn41Ser 129.72 þ 5.68 1.97 þ 0.07
hd-Asn41Ser 83.42 þ 3.76 2.03 þ 0.04
Values are means þ S.E.M. of six replicate determinations. Changes observed with di¡erent amounts of acylphosphatase were statistically signi¢cant
for both cardiac and skeletal Ca2 uptake (P6 0.01 by one-way analysis of variance). hd: heat-denatured.
Fig. 2. Coimmunoprecipitation of SERCA2a (110 kDa) and the
acylphosphatase mutant Asn41Ser (11 kDa) by monoclonal anti-
SERCA2a antibody. Immunoprecipitates were subjected to SDS
polyacrylamide gel electrophoresis and Western blot analysis using
either an anti-SERCA2a antibody or an anti-acylphosphatase anti-
body.
Fig. 1. E¡ect of di¡erent acylphosphatase concentrations on cardiac
SR Ca2-ATPase phosphoenzyme. The acylphosphatase mutant
Asn41Ser (a) was added at a concentration corresponding to 100 U
active enzyme/mg of SRV protein. Each point is the mean þ S.E.M.
of ¢ve experiments performed on di¡erent vesicle preparations. All
the changes in phosphate release induced by acylphosphatase were
statistically signi¢cant (P6 0.01 by one-way analysis of variance).
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transport (Fig. 3), but these stimulatory e¡ects were less
marked (the maximal stimulation was about 60% over the
control values) than those observed using unphosphorylated
vesicles. No signi¢cant enhancement of the rate of Ca2-ATP-
ase activity and Ca2 transport was shown using the Asn41Ser
mutant of acylphosphatase.
4. Discussion
The main goal of the present study was to establish whether
acylphosphatase, in addition to its hydrolytic activity on EP,
could stimulate the cardiac SR Ca2 pump through another
mechanism, owing to its conformational properties. To verify
this hypothesis we used a particular acylphosphatase mutant,
Asn41Ser, which for the above reasons appeared an excellent
tool for our purpose, all the more so since we observed that it
was ine¡ective even on the phosphorylated intermediate of the
cardiac SR Ca2 pump.
That being established, our ¢rst attempt in the present
study was to verify a physical interaction between acylphos-
phatase and heart SR Ca2-ATPase. In this connection, the
results that we obtained in controlled immunoprecipitation
experiments strongly suggest the possibility of a speci¢c bind-
ing between these two proteins, which were selectively co-pre-
cipitated by a monoclonal anti-SERCA2a antibody. In the
same conditions, the heat-denatured form of our mutant
was not precipitated, thus its native conformation appeared
to be required for the interaction with SR Ca2-ATPase.
Other experiments were designed to examine the e¡ect of
the Asn41Ser acylphosphatase mutant on the functional prop-
erties of SERCA2a, notably the rate of ATP hydrolysis and
Ca2 transport, and to compare these e¡ects with those pro-
duced by the active enzyme. To explore the relationship be-
tween our enzyme and phospholamban in a¡ecting the activ-
ity of Ca2 pump, the above experiments were performed
using unphosphorylated heart SRVs, the same vesicles whose
phospholamban was PKA-phosphorylated, and fast twitch
skeletal muscle SRVs where phospholamban was absent.
The Asn41Ser acylphosphatase mutant signi¢cantly stimu-
lated (although to a lesser extent than the native enzyme)
Ca2-dependent ATP hydrolysis and Ca2 transport in un-
phosphorylated cardiac SRVs, but it failed to exert this stim-
ulatory e¡ect when its three-dimensional structure was altered
by thermal denaturation or when SRV phospholamban
underwent PKA phosphorylation, an event which per se can
remove phospholamban inhibition on the Ca2 pump. Fur-
thermore, the acylphosphatase mutant did not exhibit any
e¡ect on the activity of Ca2-ATPase in skeletal muscle
SRVs lacking phospholamban. In our opinion, all these ¢nd-
ings, together with the above-mentioned speci¢c binding to
SERCA2a, are consistent with the possibility that part of
the stimulatory e¡ect of acylphosphatase on the heart SR
Ca2 pump may be ascribed to a conformational interaction
leading to a removal of phospholamban inhibition. Besides,
the more marked enhancement of Ca2-ATPase activity in-
duced by acylphosphatase in heart than in skeletal muscle
SRVs suggests a stimulatory mechanism additional to the
common e¡ect of accelerated EP hydrolysis.
Other interesting results of the present study are the di¡er-
ent e¡ects of acylphosphatase on the functional properties of
the SR Ca2-ATPases from heart and from fast twitch skel-
etal muscle. As a tentative hypothesis we propose that acyl-
phosphatase can act at various steps of the reaction sequence
involved in Ca2 transport across SR, owing to the presence
or the absence of phospholamban. In cardiac SRVs acylphos-
phatase-induced hydrolysis of EP would take place in the so-
called E2P form, that is when Ca2 ions are already trans-
located, hence a parallel increase in the rate of ATP hydrolysis
and of calcium transport. In contrast, in skeletal muscle
SRVs, where phospholamban is absent, acylphosphatase
would act on the so-called E1P form, in other words before
the Ca2 ions are translocated: this would result in the ob-
served ‘uncoupling’ e¡ect, namely a stimulation of ATP hy-
drolysis, with a concomitant inhibition of Ca2 transport. The
results of our previous studies [17,18], indicating that acyl-
phosphatase had a similar uncoupling e¡ect on other Ca2
pumps lacking phospholamban (red cell membrane and heart
sarcolemma Ca2-ATPases), might support this view.
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